Boasting various advantages over medical marijuana, the company has launched three new marijuana-derived medicines
Emerald Health Therapeutics has announced three new cannabis oil products – THCA (tetrahydrocannabinolic acid) oil, THC oil, and THC:CBD oil – which were launched via its wholly owned subsidiary, Emerald Health Botanicals.
The company markets their cannabis oils as whole cannabis plant extracts that provide users with the benefits of cannabinoids. The oils can be ingested orally with ease, eliminating dosage problems associated with inhalation.
Botanicals also boasted of being the first licensed producer in Canada to offer THCA oil. According to the release, THCA is the precursor to THC and produces no psychotropic effects. A very gentle extraction process is used to isolate THCA from cannabis. The company’s team of PhDs and MDs are doing further research and development for other possible cannabis-based products, as well as clinical studies on the health effects of cannabis and cannabinoids.
"We believe being able to provide our patients with cannabis oils in a form that can be properly dosed is a big step forward for Botanicals,” said Dr. Avtar Dhillon, chairman of therapeutics. “Oils, such as THCA, that provide the benefits of cannabis without a psychotropic effect, should be of great benefit to our patients and the medical community.”
The legalization of marijuana for medicinal purposes has been very contentious, with many objectors being concerned about side effects such as intoxication, addiction, and transitioning to more dangerous illegal drugs. In a recent poll, Ontarians have expressed support for mandatory ID checks for purchasing the substance, believing that restricting underage access should be the government’s number one concern in controlling sales.
On the other side of the issue, lobby groups such as Canadians for Fair Access to Medical Marijuana (CFAMM) and The Arthritis Society have spoken out to demand fair access to the drug.
The company markets their cannabis oils as whole cannabis plant extracts that provide users with the benefits of cannabinoids. The oils can be ingested orally with ease, eliminating dosage problems associated with inhalation.
Botanicals also boasted of being the first licensed producer in Canada to offer THCA oil. According to the release, THCA is the precursor to THC and produces no psychotropic effects. A very gentle extraction process is used to isolate THCA from cannabis. The company’s team of PhDs and MDs are doing further research and development for other possible cannabis-based products, as well as clinical studies on the health effects of cannabis and cannabinoids.
"We believe being able to provide our patients with cannabis oils in a form that can be properly dosed is a big step forward for Botanicals,” said Dr. Avtar Dhillon, chairman of therapeutics. “Oils, such as THCA, that provide the benefits of cannabis without a psychotropic effect, should be of great benefit to our patients and the medical community.”
The legalization of marijuana for medicinal purposes has been very contentious, with many objectors being concerned about side effects such as intoxication, addiction, and transitioning to more dangerous illegal drugs. In a recent poll, Ontarians have expressed support for mandatory ID checks for purchasing the substance, believing that restricting underage access should be the government’s number one concern in controlling sales.
On the other side of the issue, lobby groups such as Canadians for Fair Access to Medical Marijuana (CFAMM) and The Arthritis Society have spoken out to demand fair access to the drug.
